Descripción de la empresa
Bausch + Lomb Corporation operates as a diversified eye health company with a global footprint spanning the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and various international markets. The enterprise functions within the Healthcare sector, specifically targeting the Medical Instruments & Supplies industry, where it provides essential medical devices, pharmaceuticals, and surgical solutions across three primary segments: Vision Care, Pharmaceuticals, and Surgical. The company currently maintains a substantial scale with a market capitalization of $5.46B and generates annual revenue (TTM) of $5.10B, supported by an operational workforce of 13,000 employees. These valuation and revenue figures indicate that Bausch + Lomb holds a significant position within the niche medical device market, reflecting a robust operational presence that commands attention despite the absence of a trailing P/E ratio in current valuations.
Salud financiera
The company reported revenue (TTM) of $5.10B alongside a net income (TTM) of -$360,000,000, while generating an EBITDA of $609.00M, revealing a distinct gap between top-line performance and bottom-line profitability. This disparity indicates that the company's cost structure, including taxes and interest expenses, has been substantial enough to convert a positive operating earnings before interest and taxes into a significant net loss over the trailing twelve-month period. Despite the reported net loss, the business maintains strong cash generation capabilities with a free cash flow of $141.38M, which provides the necessary financial flexibility to fund operations, service debt obligations, or pursue strategic investments without relying on external financing. The margin profile presents a mixed picture, featuring a gross margin of 59.8% that suggests efficient production and pricing power, contrasted by an operating margin of 11.2% and a profit margin of -7.1% that highlights the pressure from fixed costs and interest burdens. In terms of leverage, the company holds $383.00M in cash against total debt of $5.25B, resulting in a debt-to-equity ratio of 80.46, which characterizes a highly leveraged balance sheet where debt obligations significantly outweigh equity and liquid assets. Liquidity remains manageable with a current ratio of 1.55, indicating that the company possesses 1.55 times more current assets than current liabilities to meet short-term obligations. Return metrics further illustrate the financial strain, with a return on equity of -5.4% and a return on assets of 0.9%, suggesting that management has struggled to generate value for shareholders and utilize the asset base effectively to produce net profits.
Evaluación de valoración
Valuation metrics for Bausch + Lomb reflect the challenges associated with its current earnings position, showing a forward P/E of 14.36 while the trailing P/E (TTM) remains N/A due to the negative net income. The absence of a trailing P/E ratio implies that traditional valuation based on past earnings is currently inapplicable, whereas the forward P/E suggests the market is pricing in a potential recovery in profitability for the coming year. The stock trades at a price-to-book ratio of 0.84, indicating that the market values the company at less than its book value, which often signals a perception of undervaluation or underlying concerns regarding future earnings potential. Alternative valuation measures, including a price-to-sales ratio of 1.07 and an EV/EBITDA of 17.04, provide context by linking the stock price directly to revenue generation and operating cash flow, offering a clearer picture of valuation relative to sales volume and operational efficiency. Price momentum is defined by a 52-week high of $18.91 and a 52-week low of $10.45, meaning the current price sits somewhere within this range, reflecting the volatility typical of a company with a beta of 0.58. The beta of 0.58 indicates that the stock is less volatile than the broader market, moving only 58% as much as the market index, which provides a degree of stability for investors seeking lower correlation to general market fluctuations.
Growth & Income
The company demonstrated a revenue growth (YoY) of 9.8%, while earnings growth (YoY) is listed as N/A, highlighting a situation where top-line expansion does not immediately translate into bottom-line growth due to the current net loss. Since earnings growth is not applicable, the expansion of revenue does not yet correlate with proportional earnings increases, suggesting that the benefits of growth are being absorbed by the high fixed costs and interest expenses inherent in the company's leveraged structure. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are retained to support operations and reduce debt rather than being distributed to shareholders. This reinvestment strategy is a common approach for leveraged companies attempting to deleverage their balance sheet before returning capital to investors, prioritizing financial stability over immediate income returns. The overall growth and income profile is characterized by strong top-line expansion in the vision care and surgical segments but is currently constrained by profitability challenges, resulting in a scenario where investors must wait for earnings normalization to access income through dividends or share price appreciation.